Geoffrey Craig Porges net worth and biography

Geoffrey Porges Biography and Net Worth

CFO of Schrodinger

Geoff Porges, MBBS., is Chief Financial Officer. He joined Schrödinger in 2022 to lead the company’s financial operations, investor relations and corporate affairs activities, and business development and strategic planning for the company’s proprietary pharmaceuticals and biopharmaceutical collaborations. Geoff joined Schrödinger from SVB Securities, where he was most recently vice chairman. From 2015 until 2022, he was senior managing director, director of therapeutics research and senior research analyst at SVB Securities and at Leerink prior to its acquisition by SVB Securities. In that capacity, he led the Leerink/SVB therapeutics research team and personally provided research coverage for established and emerging diversified biopharmaceutical companies. Prior to joining SVB Securities, he was the biotechnology research analyst at Alliance Bernstein for 13 years. Earlier in his career, Geoff held executive positions at BTG plc and Merck, including leading the commercialization of Merck’s human vaccines. Geoff earned his medical degree from the University of Sydney and trained in pediatric and internal medicine in Australia. He is also a graduate of Harvard Business School where he was a Baker Scholar.

What is Geoffrey Craig Porges' net worth?: The estimated net worth of Geoffrey Craig Porges is at least $507.36 thousand as of March 3rd, 2025. Porges owns 27,544 shares of Schrodinger stock worth more than $507,360 as of December 5th. This net worth approximation does not reflect any other assets that Porges may own. Learn More about Geoffrey Craig Porges' net worth.
How do I contact Geoffrey Craig Porges?: The corporate mailing address for Porges and other Schrodinger executives is 120 WEST 45TH STREET 17TH FLOOR, NEW YORK NY, 10036. Schrodinger can also be reached via phone at 212-295-5800 and via email at [email protected]. Learn More on Geoffrey Craig Porges' contact information.
Has Geoffrey Craig Porges been buying or selling shares of Schrodinger?: Geoffrey Craig Porges has not been actively trading shares of Schrodinger during the past quarter. Most recently, Geoffrey Craig Porges sold 5,491 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $21.76, for a transaction totalling $119,484.16. Following the completion of the sale, the chief financial officer now directly owns 27,544 shares of the company's stock, valued at $599,357.44. Learn More on Geoffrey Craig Porges' trading history.
Who are Schrodinger's active insiders?: Schrodinger's insider roster includes Robert Abel (Insider), Karen Akinsanya (Insider), Margaret Dugan (Insider), Jenny Herman (SVP), Rosana Kapeller-Libermann (Director), Joel Lebowitz (CFO), Kenneth Lorton (COO), Geoffrey Porges (CFO), David Shaw (Major Shareholder), Yvonne Tran (EVP), and Jorg Weiser (Director). Learn More on Schrodinger's active insiders.
Are insiders buying or selling shares of Schrodinger?: During the last twelve months, insiders at the sold shares 3 times. They sold a total of 23,609 shares worth more than $568,456.88. The most recent insider tranaction occured on October, 16th when insider Margaret Dugan sold 1,395 shares worth more than $29,392.65. Insiders at Schrodinger own 21.0% of the company. Learn More about insider trades at Schrodinger.
Information on this page was last updated on 10/16/2025.

Geoffrey Craig Porges Insider Trading History at Schrodinger

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/3/2025	Sell	5,491	$21.76	$119,484.16	27,544

Geoffrey Craig Porges Buying and Selling Activity at Schrodinger

Schrodinger Company Overview

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Today's Range

Now: $18.42

$17.50

$18.42

50 Day Range

MA: $19.32

$16.33

$22.52

2 Week Range

Now: $18.42

$15.99

$28.47

Volume

720,261 shs

Average Volume

975,070 shs

Market Capitalization

$1.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56